TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05029596
Drug: Heparin Group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
Study: NCT02714673
Drug: anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
Study: NCT01996735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04023695
Drug: Corticosteroid with lidocaine with epinephrine
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger finger injection
Study: NCT04095286
Drug: AMB new formulation (1 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
Study: NCT04095286
Drug: Reference AMB (5 mg)
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
Study: NCT02216331
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description.
Study: NCT03870711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water 4 puffs
Study: NCT01477190
Drug: Spinal analgesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged \> 75 years.
Study: NCT00313807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Saline Infusion
Study: NCT02819310
Drug: BLI400 Laxative
Normalized name: LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral laxative
Study: NCT04243083
Drug: TLL018 tablet, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral QD
Study: NCT00080873
Drug: Traumeel S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02388360
Drug: topical prostaglandin analogs
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04688346
Drug: HemeRX epinephrine pellets
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Racemic Epinephrine Pellet
Study: NCT03276936
Drug: FMX103 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMX103 1.5% minocycline foam
Study: NCT03041116
Drug: Fosmetpantotenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing
Study: NCT03041116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing
Study: NCT01598857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03333057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution (0.9% sodium chloride solution)
Study: NCT02029794
Drug: 3-5% acetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00137852
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
Study: NCT04022811
Drug: 0.1% bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
Study: NCT02037802
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02849990
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04397406
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
Study: NCT04218916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules once, three times a day
Study: NCT01902082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01072097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 6 months
Study: NCT02676076
Drug: CHF 5993 100/6/12.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02676076
Drug: CHF 1535 100/6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00863785
Drug: Corticoids plus N Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
Study: NCT02544906
Drug: dexmedetomedine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
Study: NCT02116465
Drug: Levodopa Carbidopa immediate release tablets
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01775891
Drug: other class IC antiarrhythmic drug
Normalized name: Antiarrhythmics, class Ic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
Study: NCT03497325
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
Study: NCT04423965
Drug: mFOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 165 mg/m² IV day 1+ oxaliplatin 85 mg/m² IV day 1 + leucovorin 400 mg/m² day 1, fluorouracil 1200mg/m²/day \*2 days (total 2400 mg/m² over 48 hours) continuous infusion starting on day 1 of each 2 weeks cycle
Study: NCT00389896
Drug: MK0733 / Duration of Treatment: 18 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00389896
Drug: Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03791125
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
Study: NCT00142480
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
Study: NCT01883440
Drug: Saline+glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm
Study: NCT03736538
Drug: Placebo gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
Study: NCT00972244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, 12 weeks
Study: NCT00335504
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00335504
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02216253
Drug: L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
Study: NCT01986569
Drug: [18F]fluoroestradiol (FES)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]FES PET/CT will be performed 90 min (± 10 min) after administration of \[18F\]FES. Patients will undergo core needle biopsy or surgery within 15 days after \[18F\]FES PET; or patients will undergo core needle biopsy within 30 days before \[18F\]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
Study: NCT02930798
Drug: BAY987516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-116)
Study: NCT03554005
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
Study: NCT02542605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once on day 1 of Part B of the study by intravenous infusion.
Study: NCT02542605
Drug: PACAP-38 Challenge Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.
Study: NCT02280291
Drug: Ankle SSB
Normalized name: Bos taurus ankle joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
Study: NCT02280291
Drug: Ankle OnQ
Normalized name: Bos taurus ankle joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
Study: NCT03165136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo of hydroxychloroquine
Study: NCT00065741
Drug: silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01636024
Drug: AZD7594
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension inhaled via Spira nebuliser
Study: NCT01636024
Drug: Placebo to match
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo inhaled via Spira nebuliser
Study: NCT00385268
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT01157416
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
Study: NCT04156750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01975779
Drug: Cohort A2: Lu AE58054 or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
Study: NCT01975779
Drug: Cohort B1: Lu AE58054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two single oral doses 60 mg with \>=7 days washout.
Study: NCT01005719
Drug: Prevacid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
Study: NCT01368341
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet, 100 mg, b.i.d. 14 days
Study: NCT00412698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
Study: NCT04405505
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT02918487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive compound that is similar looking as the intervention
Study: NCT01669369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
Study: NCT01350037
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
Study: NCT01617434
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
Study: NCT03682094
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.
Study: NCT02930655
Drug: Enzyme replacement therapy (ERT)
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
Study: NCT00659919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02998437
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
Study: NCT02662660
Drug: Metamizole and Acetaminophen iv
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
Study: NCT02213289
Drug: ABT-806
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-806
Study: NCT00307060
Drug: MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02213289
Drug: Standard cytotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
Study: NCT03417180
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
Study: NCT00248313
Drug: Rapamune®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02932475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered to match active drug
Study: NCT01448291
Drug: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
Study: NCT01323257
Drug: erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
Study: NCT01323257
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsule once daily for 7 days (Trt A, C, D)
Study: NCT01323257
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsule once daily for 7 days (Trt F)
Study: NCT01323257
Drug: erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg tablets three times a day for 7 days (Trt C)
Study: NCT03462446
Drug: Vitamin K antagonists (VKAs)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
Study: NCT02476981
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
Study: NCT01689207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART A, PART B, PART C: matching placebo IV infusions
Study: NCT00364845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefilled syringe placebo, to match active arm
Study: NCT03705962
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02624401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of saline (Ringer's Acetate)
Study: NCT02614872
Drug: GLASSIA® and Institution standard of care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)
Study: NCT00649467
Drug: Topamax® Sprinkle Capsules 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg, single dose applesauce
Study: NCT03765801
Drug: GRTA9906 60 mg PR tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRTA9906 60 mg PR tablet
Study: NCT03765801
Drug: GRTA9906 60 mg IR capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRTA9906 60 mg IR capsule
Study: NCT03141086
Drug: LML134
Approvals — FDA: no, EMA: no, PMDA: no
Description: LML134
Study: NCT03141086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00088634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo to 40mg lurasidone tablets
Study: NCT02150824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 high dose matching placebo once daily
Study: NCT02150824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 medium dose matching placebo once daily
Study: NCT02150824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 high dose matching placebo once daily add on to background metformin
Study: NCT00524316
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transarterial chemoembolization
Study: NCT02884817
Drug: Experimental: essential oils and ELA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
Study: NCT02619019
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
Study: NCT04035135
Drug: ANX005
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational drug
Study: NCT00147004
Drug: hydrocortisone sodium succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
Study: NCT00147004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00013624
Drug: IV Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01803763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
Study: NCT02929563
Drug: Placebo (for pantoprazole)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03638726
Drug: Atropine sulfate and epinephrine
Normalized name: atropine / epinephrine / tyramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.
Study: NCT04552535
Drug: Second line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy